Posts tagged lead development
ContraVir Pharma to merge with Ciclofilin Pharma

ContraVir Pharmaceuticals (NASDAQ:CTRV) has entered into a definitive merger agreement with closely-held Ciclofilin Pharmaceuticals.

Under the accord, ContraVir will acquire all of the outstanding equity interests in Ciclofilin for the right to receive future milestone payments, which will be allocated among the holders of Ciclofilin common stock.

Read More